Biosimilar Antibodies & Proteins
In this product category, you will find reports and other services providing you with the most uptodate business and competitive intelligence information on biosimilar antibodies and proteins. The range of products covers industry data as well as in-depth strategic assessment and analysis of biosimilar antibody and protein companies, R&D pipeline, and sales and market information.
Subscribe to
our newsletters!
Showing all 18 resultsSorted by latest
-
March of 20252024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA€ 130.00
-
July of 2024This product provides basic information on drugs on the market and drug candidates in R&D as biosimilar antibodies of Actemra/RoActemra (tocilizumab).€ 200.00
-
July of 2024This product provides basic information on drug candidates in research and development as biosimilar antibodies of Keytruda (pembrolizumab)€ 200.00
-
March of 2024This product provides basic information on approved and investigational antibodies, cell therapies and small molecules targeting CD38.€ 300.00
-
March of 20242023 sales data of originator therapeutic proteins and antibodies, selected biosimilars and other biologic drug modalities (gene & cell therapy, RNA)€ 130.00
-
March of 2025Online database of annual global sales of innovator & bioimilar biologics since the year 2007€ 250.00
-
On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Prolia & Xgeva (denosumab).€ 300.00
-
July of 2023This report provides a competitor evaluation in the field of antibodies, proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor€ 400.00
-
On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Humira (adalimumab).€ 400.00
-
On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Soliris (eculizumab).€ 300.00
-
On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Xolair (omalizumab).€ 300.00
-
On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Lucentis (ranibizumab)€ 300.00
-
On the same day of purchaseThis product provides basic information on drug candidates in R&D as biosimilar antibodies of Eylea (aflibercept)€ 300.00
-
On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Stelara (ustekinumab).€ 300.00
-
March of 2023Sales data of originator therapeutic proteins and antibodies & selected biosimilar antibodies and proteins and other biologics in 2022€ 120.00
-
February of 2023Antibody Target, Technology & Pipeline Database€ 1600.00
-
March of 2022This report provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2021€ 100.00
-
December of 2019Competitive intelligence report about next wave biosimilar antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More as of December 2019€ 600.00